Skip to Main Content

As the price of new medicines weighs on health payers in Europe, universities are seeking a greater stake in how their research is used and trying to attach conditions on the use of intellectual property to ensure access and affordability of the final product. But getting this done, universities and other advocates are learning, isn’t easy.

At the forefront of this movement are groups such as Universities Allied for Essential Medicines, which for years has been urging universities to include terms and conditions on access and affordability into their research agreements with pharmaceutical companies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment